With the clinical benefit of adjuvant trastuzumab alongside the escalating costs of cancer treatments, we sought to assess the cost-effectiveness of the TH regimen as compared to standard of care, ACTH and TCH regimens for small, node-negative HER2-positive breast cancer in the United States using a Markov modeling approach. This evidence concerns the gene ERBB2 and cancer.